Ixabepilone proved efficacy against OS resistant tumors

Patients with highly aggressive, chemoresistant osteosarcoma (OS) continues to represent a population with unmet need. There has historically been a limited number of relevant models that well represent the heterogeneity of OS to be used for discovering efficient novel drugs. We have enlarged the already available collections of patient derived xenograft (PDX) with 30 additional models that depict the epidemiologic, genetic, and biological features of OS and we have established six, new PDX-derived cell lines as a resource to generate solid preclinical findings to guide treatments for patients with these aggressive malignancies. Drug screening of 2800 FDA-approved compounds led to identification of five repurposed drugs, including ixabepilone that was selected as the most effective agent against highly aggressive OS with features of innate and/or acquired chemoresistance.